3+ day, 23+ hour ago   (568+ words) Life sciences dealmaking hits record highs as biopharma bets big on early-stage assets amid geopolitical uncertainty. The first half of 2026 has delivered the strongest run of life sciences dealmaking on record, according to a report published by EY - a long-term…...

5+ day, 20+ hour ago   (654+ words) Sernova and Seraxis merge to create integrated cell replacement platform, with $10 million financing secured to advance lead candidate toward clinical trial in 2027. A new player in the type 1 diabetes (T1D) treatment landscape is taking shape as Sernova Biotherapeutics and Seraxis Holdings…...

5+ day, 20+ hour ago   (402+ words) Moonwalk Biosciences has closed a $70 million Series B to push adipose-targeted RNAi obesity candidate into the clinic. Moonwalk is developing small interfering RNA (siRNA) therapeutics designed to act directly on adipose tissue, targeting non-incretin biology inside the fat cell itself....

3+ week, 2+ day ago   (1006+ words) Marc Appel, founder of Pacific Bridge, an investment firm specializing in Asian biotech, spoke with BioXconomy about China’s rise in the biotech sector and how this transformation is reshaping drug development, accelerating patient access to new therapies, and creating both…...